Nautilus Biotechnology (NAUT) Equity Ratio (2020 - 2026)

Nautilus Biotechnology has disclosed Equity Ratio across 7 years of filings, most recently posting 0.81 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.81, down 4.87% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.81 (down 4.87% YoY), and the FY2025 annual result was 0.82, down 4.48% from the prior year.
• Equity Ratio came in at 0.81 for Q1 2026 at Nautilus Biotechnology, down from 0.82 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2022 to a low of 0.81 in Q1 2026.
• The 5-year median for Equity Ratio is 0.86 (2024), against an average of 0.87.
• Peak annual rise in Equity Ratio reached 471.84% in 2022, while the deepest fall reached 8.43% in 2022.
• Nautilus Biotechnology's Equity Ratio stood at 0.9 in 2022, then fell by 3.47% to 0.87 in 2023, then retreated by 0.98% to 0.86 in 2024, then retreated by 4.48% to 0.82 in 2025, then declined by 1.1% to 0.81 in 2026.
• The last three Equity Ratio figures came in at 0.81 (Q1 2026), 0.82 (Q4 2025), and 0.84 (Q3 2025), per Business Quant data.